CRVO Stock — CervoMed Inc.

CervoMed Inc. (CRVO)

Updated October 16, 2026.

CRVO is a Stock. Its deepest 1-year drawdown was 77.5%.

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders, primarily focusing on neflamapimod, an orally administered small molecule drug designed to inhibit the enzyme p38a and potentially reverse synaptic dysfunction in conditions including dementia with Lewy bodies, primary progressive aphasia, and amyotrophic lateral sclerosis. The company does not currently distribute income to shareholders. CervoMed appeals to investors seeking exposure to early-stage neurology drug development rather than those seeking current income.

CRVO performance

Returns are updating. CRVO's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 77.5%.

CRVO key facts

Asset type

Stock

Asset class

Equity

Inception date

07/03/1996

Distribution frequency

None

Last close

$2.24 (as of 2026-10-16)

Market cap

$33,866,775

Average volume

98726.0

Payment date

12/14/2018

Beta

-4.3

Payout ratio

0.0%

EPS

$-3.21

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CRVO risks and drawbacks

The deepest 1-year drawdown on record here is 77.5%.

Who may consider CRVO — and who may not

It is a weaker fit for investors who need monthly cash flow (CRVO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CRVO

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions